Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge

Mucosal COVID-19 vaccines are needed to block SARS-CoV-2 infection at the mucosal site. Intranasal delivery of a glycosylated Delta variant receptor-binding domain (Delta-RBD) mucosal vaccine elicited potent and balanced systemic antibody titers comparable to those induced by the intramuscular injec...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xiaoqing, Verma, Abhishek K., Wang, Gang, Shi, Juan, Perlman, Stanley, Du, Lanying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563057/
https://www.ncbi.nlm.nih.gov/pubmed/37822493
http://dx.doi.org/10.1016/j.isci.2023.108033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563057/
https://www.ncbi.nlm.nih.gov/pubmed/37822493
http://dx.doi.org/10.1016/j.isci.2023.108033

Ejemplares similares